The benefit of enzalutamide was shown with respect to all secondary end points , including the time until the initiation of cytotoxic chemotherapy ( hazard ratio , @ ) , the time until the first skeletal-related event ( hazard ratio , @ ) , a complete or partial soft-tissue response ( @ % vs. @ % ) , the time until prostate-specific antigen ( PSA ) progression ( hazard ratio , @ ) , and a rate of decline of at least @ % in PSA ( @ % vs. @ % ) ( P < @ for all comparisons ) .